What is claimed is:

1. Use of a compound selected from the group consisting of diacerein, rhein, monoacetylrhein, salts, and esters, thereof, in the manufacture of a medicament for the treatment of atopic dermatitis (AD) in a subject in need thereof.

2. The use of Claim 1, wherein the subject is a human.

3. The use of Claim 1, wherein the compound is to be administered at a dose of 5 to 500 mg per day.